Thomas Vanassche
Universitair Ziekenhuis Leuven(BE)LMU Klinikum(DE)Institut d'Investigació Biomédica de Bellvitge(ES)Department of Health(ES)VIB-KU Leuven Center for Microbiology(BE)Hospital São Rafael(BR)Imperial Consultants(GB)Instituto Biofisika(ES)University Hospital Cologne(DE)Karl Landsteiner Society(AT)Ludwig-Maximilians-Universität München(DE)University of Palermo(IT)KU Leuven(BE)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Venous Thromboembolism Diagnosis and Management, Antiplatelet Therapy and Cardiovascular Diseases, Cardiac Arrhythmias and Treatments, Antimicrobial Resistance in Staphylococcus
Most-Cited Works
- → 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation(2021)1,044 cited
- → Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial(2017)864 cited
- → Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant(2019)478 cited
- → Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES(2014)311 cited
- → Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study(2022)300 cited
- →